Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?
et al., Medical Hypotheses, doi:10.1016/j.mehy.2020.109815, Apr 2020 (preprint)
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Hypothesis that HCQ/CQ + zinc will be more effective than HCQ/CQ alone for COVID-19.
Study covers zinc and HCQ.
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Monsalve et al., NETosis: A key player in autoimmunity, COVID-19, and long COVID, Journal of Translational Autoimmunity, doi:10.1016/j.jtauto.2025.100280.
3.
Xie et al., The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
4.
Gkioulekas et al., Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2, Tasman Medical Journal, 6:4, tasmanmedicaljournal.com/2024/10/use-of-hydroxychloroquine-in-multidrug-protocols-for-sars-cov-2a/.
5.
Gortler et al., Those Published “17,000 Hydroxychloroquine Deaths” Never Happened, Brownstone Journal, brownstone.org/articles/those-published-17000-hydroxychloroquine-deaths-never-happened/.
6.
Boretti et al., Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses, doi:10.2174/0126667975327612240902104505.
7.
Gortler (B) et al., Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America, Brownstone Journal, brownstone.org/articles/trumps-63-million-doses-of-hydroxychloroquine-could-have-been-great-for-america/.
8.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
9.
Asaba et al., Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections, Journal of Inflammation Research, doi:10.2147/jir.s474707.
10.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
11.
Ali et al., SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication, Journal of Clinical Medicine, doi:10.3390/jcm12186079.
12.
Brouqui et al., There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view, New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155.
13.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
14.
Boretti (B), A., Pharmacotherapy for Covid-19 infection in the countries of the Cooperation Council for the Arab States, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2021.08.005.
15.
Vigbedor et al., Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825.
16.
Kaur et al., Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?, Medical Hypotheses, doi:10.1016/j.mehy.2021.110539.
17.
Raoult, D., Rational for meta-analysis and randomized treatment: the COVID-19 example, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.012.
18.
Matada et al., A comprehensive review on the biological interest of quinoline and its derivatives, Bioorganic & Medicinal Chemistry, doi:10.1016/j.bmc.2020.115973.
19.
IHU, Natural history and therapeutic options for COVID-19, Expert Review of Clinical Immunology, www.mediterranee-infection.com/wp-content/uploads/2020/09/ERM-2020-0073.R1_Proof_hi.pdf.
20.
Hecel et al., Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?, Pharmaceuticals, 13:9, 228, doi:10.3390/ph13090228.
21.
Li et al., Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease volume 11, doi:10.1038/s41419-020-2721-8.
22.
Goldstein, L., Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys, Preprint, July 7, 2020, wattsupwiththat.com/2020/07/07/hydroxychloroquine-based-covid-19-treatment-a-systematic-review-of-clinical-evidence-and-expert-opinion-from-physicians-surveys/.
23.
Roussel et al., Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes and New Infections, Volume 38
, doi:10.1016/j.nmni.2020.100710.
24.
Mo et al., Chloroquine phosphate: therapeutic drug for COVID-19, Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22.
25.
Gao et al., Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19), Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072.
26.
Derwand et al., Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Medical Hypotheses, doi:10.1016/j.mehy.2020.109815.
27.
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945.
28.
Todaro et al., An Effective Treatment for Coronavirus (COVID-19), github.com/covidtrial/info/raw/master/An%20Effective%20Treatment%20for%20Coronavirus%20(COVID-19).pdf.
Derwand et al., 6 Apr 2020, peer-reviewed, 2 authors.
Contact: martin.scholz@leukocare.com.
Does zinc supplementation enhance the clinical efficacy of chloroquine/ hydroxychloroquine to win today's battle against COVID-19?
Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials.
Conflict of interest The author Roland Derwand is/was at the time of writing an employee of Alexion Pharma Germany GmbH. The author Martin Scholz is/was at the time of writing External Senior Advisor for the company LEUKOCARE in Munich, Germany. The authors confirm that this article content has no conflict of interest.
References
Anderson, Roussel, Zouari, Mahjoub, Matheau et al., Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus, J Am Coll Nutr
Braun, Rosenfeldt, Pharmaco-nutrient interactions -a systematic review of zinc and antihypertensive therapy, Int J Clin Pract
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105932
Cui-Cui, Rw, Repurposing host-based therapeutics to control coronavirus and influenza virus, Drug Discovery Today
Ervin, Kennedy-Stephenson, Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey, J Nutr
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Kaushik, Subramani, Anang, Zinc salts block hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase, J Virol, doi:10.1128/JVI.00754-17
Kearney, Chloroquine as a potential treatment and prevention measure for the 2019 novel coronavirus: a review, Preprints, doi:10.20944/preprints202003.0275
Kupferschmidt, Cohen, WHO launches global megatrial of the four most promising coronavirus treatments, Science
Prasad, Beck, Bao, Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress, Am J Clin Nutr
Read, Obeid, Ahlenstiel, Ahlenstiel, The role of zinc in antiviral immunity, Adv Nutr, doi:10.1093/advances/nmz013
Rolain, Colson, Raoult, Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century, Int J Antimicrob Agents
Smith, Bushek, Prosser, COVID-19 drug therapy potential options
Velthuis, Van Den Worm, She, Sims, Zn 2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog, doi:10.1371/journal.ppat.1001176
Xue, Moyer, Peng, Wu, Hannafon et al., Chloroquine is a zinc ionophore, PLoS One, doi:10.1371/journal.pone.0109180
Yang, Shen, Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19, Int J Biol Sci, doi:10.7150/ijbs.45498
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
DOI record:
{
"DOI": "10.1016/j.mehy.2020.109815",
"ISSN": [
"0306-9877"
],
"URL": "http://dx.doi.org/10.1016/j.mehy.2020.109815",
"alternative-id": [
"S0306987720306435"
],
"article-number": "109815",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "Medical Hypotheses"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.mehy.2020.109815"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2020 The Authors. Published by Elsevier Ltd."
}
],
"author": [
{
"affiliation": [],
"family": "Derwand",
"given": "R.",
"sequence": "first"
},
{
"affiliation": [],
"family": "Scholz",
"given": "M.",
"sequence": "additional"
}
],
"container-title": "Medical Hypotheses",
"container-title-short": "Medical Hypotheses",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.jp",
"clinicalkey.com",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.fr",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2020,
5,
6
]
],
"date-time": "2020-05-06T21:06:39Z",
"timestamp": 1588799199000
},
"deposited": {
"date-parts": [
[
2020,
10,
6
]
],
"date-time": "2020-10-06T21:01:40Z",
"timestamp": 1602018100000
},
"indexed": {
"date-parts": [
[
2023,
3,
22
]
],
"date-time": "2023-03-22T07:54:17Z",
"timestamp": 1679471657683
},
"is-referenced-by-count": 112,
"issued": {
"date-parts": [
[
2020,
9
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
9,
1
]
],
"date-time": "2020-09-01T00:00:00Z",
"timestamp": 1598918400000
}
},
{
"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
5,
6
]
],
"date-time": "2020-05-06T00:00:00Z",
"timestamp": 1588723200000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0306987720306435?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0306987720306435?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "109815",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
9
]
]
},
"published-print": {
"date-parts": [
[
2020,
9
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"key": "10.1016/j.mehy.2020.109815_b0005",
"unstructured": "https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 [consulted on 2020-04-22]."
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
"author": "Zhou",
"doi-asserted-by": "crossref",
"first-page": "1054",
"issue": "10229",
"journal-title": "Lancet",
"key": "10.1016/j.mehy.2020.109815_b0010",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.1016/j.drudis.2019.01.018",
"article-title": "Repurposing host-based therapeutics to control coronavirus and influenza virus",
"author": "Cui-Cui",
"doi-asserted-by": "crossref",
"first-page": "726",
"issue": "3",
"journal-title": "Drug Discovery Today",
"key": "10.1016/j.mehy.2020.109815_b0015",
"volume": "24",
"year": "2019"
},
{
"key": "10.1016/j.mehy.2020.109815_b0020",
"unstructured": "Smith T, Bushek J, Prosser, T. COVID-19 drug therapy potential options. Clinical drug information, clinical solutions. https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf [consulted on 2020-03-28]."
},
{
"DOI": "10.1016/j.ijantimicag.2020.105932",
"article-title": "Chloroquine and hydroxychloroquine as available weapons to fight COVID-19",
"author": "Colson",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.mehy.2020.109815_b0025",
"year": "2020"
},
{
"DOI": "10.5582/bst.2020.01047",
"article-title": "Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
"author": "Gao",
"doi-asserted-by": "crossref",
"first-page": "72",
"issue": "1",
"journal-title": "Biosci Trends",
"key": "10.1016/j.mehy.2020.109815_b0030",
"volume": "14",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
"author": "Gautret",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents.",
"key": "10.1016/j.mehy.2020.109815_b0035",
"year": "2020"
},
{
"DOI": "10.20944/preprints202003.0275.v1",
"doi-asserted-by": "crossref",
"key": "10.1016/j.mehy.2020.109815_b0040",
"unstructured": "Kearney J. Chloroquine as a potential treatment and prevention measure for the 2019 novel coronavirus: a review. Preprints 2020. Doi: 10.20944/preprints202003.0275.v1. published online Mar 17."
},
{
"article-title": "WHO launches global megatrial of the four most promising coronavirus treatments",
"author": "Kupferschmidt",
"journal-title": "Science",
"key": "10.1016/j.mehy.2020.109815_b0045",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2001282",
"article-title": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19",
"author": "Cao",
"doi-asserted-by": "crossref",
"journal-title": "N Engl J Med",
"key": "10.1016/j.mehy.2020.109815_b0050",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2007.05.015",
"article-title": "Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century",
"author": "Rolain",
"doi-asserted-by": "crossref",
"first-page": "297",
"issue": "4",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.mehy.2020.109815_b0055",
"volume": "30",
"year": "2007"
},
{
"DOI": "10.7150/ijbs.45498",
"article-title": "Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19",
"author": "Yang",
"doi-asserted-by": "crossref",
"first-page": "1724",
"issue": "10",
"journal-title": "Int J Biol Sci",
"key": "10.1016/j.mehy.2020.109815_b0060",
"volume": "16",
"year": "2020"
},
{
"DOI": "10.1371/journal.pone.0109180",
"article-title": "Chloroquine is a zinc ionophore",
"author": "Xue",
"doi-asserted-by": "crossref",
"journal-title": "PLoS One",
"key": "10.1016/j.mehy.2020.109815_b0065",
"volume": "9",
"year": "2014"
},
{
"DOI": "10.1093/advances/nmz013",
"article-title": "The role of zinc in antiviral immunity",
"author": "Read",
"doi-asserted-by": "crossref",
"first-page": "696",
"journal-title": "Adv Nutr",
"key": "10.1016/j.mehy.2020.109815_b0070",
"volume": "10",
"year": "2019"
},
{
"DOI": "10.1128/JVI.00754-17",
"article-title": "Zinc salts block hepatitis E virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase",
"author": "Kaushik",
"doi-asserted-by": "crossref",
"journal-title": "J Virol",
"key": "10.1016/j.mehy.2020.109815_b0075",
"volume": "91",
"year": "2017"
},
{
"DOI": "10.1371/journal.ppat.1001176",
"article-title": "Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture",
"author": "te Velthuis",
"doi-asserted-by": "crossref",
"journal-title": "PLoS Pathog",
"key": "10.1016/j.mehy.2020.109815_b0080",
"volume": "6",
"year": "2010"
},
{
"DOI": "10.1111/ijcp.12040",
"article-title": "Pharmaco-nutrient interactions – a systematic review of zinc and antihypertensive therapy",
"author": "Braun",
"doi-asserted-by": "crossref",
"first-page": "715",
"journal-title": "Int J Clin Pract",
"key": "10.1016/j.mehy.2020.109815_b0085",
"volume": "67",
"year": "2013"
},
{
"DOI": "10.1080/07315724.2001.10719034",
"article-title": "Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus",
"author": "Anderson",
"doi-asserted-by": "crossref",
"first-page": "212",
"issue": "3",
"journal-title": "J Am Coll Nutr",
"key": "10.1016/j.mehy.2020.109815_b0090",
"volume": "20",
"year": "2001"
},
{
"DOI": "10.1093/jn/132.11.3422",
"article-title": "Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey",
"author": "Ervin",
"doi-asserted-by": "crossref",
"first-page": "3422",
"issue": "11",
"journal-title": "J Nutr",
"key": "10.1016/j.mehy.2020.109815_b0095",
"volume": "132",
"year": "2002"
},
{
"key": "10.1016/j.mehy.2020.109815_b0100",
"unstructured": "National Institutes of Health. Office of dietary supplements. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/#en2 [consulted on 2020-03-29]."
},
{
"DOI": "10.1093/ajcn/85.3.837",
"article-title": "Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress",
"author": "Prasad",
"doi-asserted-by": "crossref",
"first-page": "837",
"issue": "3",
"journal-title": "Am J Clin Nutr",
"key": "10.1016/j.mehy.2020.109815_b0105",
"volume": "85",
"year": "2007"
},
{
"key": "10.1016/j.mehy.2020.109815_b0110",
"unstructured": "https://www.ema.europa.eu/en/news/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes [consulted on 2020-04-02]."
}
],
"reference-count": 22,
"references-count": 22,
"relation": {
"has-preprint": [
{
"asserted-by": "object",
"id": "10.20944/preprints202004.0124.v1",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0306987720306435"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Medicine"
],
"subtitle": [],
"title": "Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "142"
}
derwand2
